Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Exclusion Criteria

• •Pregnant or nursing woman or woman planning to get pregnant during the study
• •Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab
• •Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks)
• •Active skin infections unrelated to atopic dermatitis
• •Severe dermatologic conditions requiring immediate medical intervention
• •Use of topical or systemic treatment during previous weeks liable to interfere with assessment
• •Subject having undergone surgery under general anaesthesia within the previous month
• •Excessive exposure to sunlight or UV-rays within the previous month
• •Subject having scars, tattoos on the forearms that would interfere with assessments
• •Subject enrolled in another clinical trial during the study period and/or during the past 30 days